The biopharmaceutical company Apogenix GmbH today announced that it has received an additional € 2.3 million BMBF grant (German Federal Ministry of Education and Research) for the further advancement of its lead substance APG101. Apogenix will use the proceeds to develop APG101 for the treatment of myelodysplastic syndromes (MDS). More specifically, the grant will be used for the production of clinical material and for the development of a biomarker program.
APG101 is a first-in-class, fully human protein that provides an innovative therapeutic approach to treating solid tumors such as Glioblastoma Multiforme (GBM). APG101 is the most advanced inhibitor of the CD95 ligand (CD95L) in clinical development. In September 2011, Apogenix announced the completion of patient recruitment of its phase II clinical trial in GBM. Final results of this trial are expected in the first quarter of 2012.Dr Thomas Höger, CEO/CFO of Apogenix commented: „This grant, along with the grants we have been awarded over the last five years totaling more than € 6 million, plays a substantial role in the development of our lead substance APG101 for the treatment of life-threatening diseases with a high unmet medical need. We are happy that we have received one of the highest BMBF grants as partner of the Biotech Cluster Rhine-Neckar. This allows us to develop APG101 for a new, promising indication, namely MDS. We firmly believe that the therapeutic potential of APG101 goes far beyond the treatment of GBM and that we have a realistic chance to show proof-ofconcept in a phase II trial planned for 2013.“
More information:Dr. Thomas HögerCEO/CFOApogenix GmbHPhone: +49 (0) 6221/ 5 86 08 - 0 E-Mail: contact(at)apogenix.com